Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 397 publications
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310.
Journal: The New England journal of medicine
Published: August 28, 2026
Venous Thromboembolism Risk and Lipid-Lowering Therapy-Reply.
Journal: JAMA cardiology
Published: August 26, 2026
Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial.
Journal: Circulation
Published: August 18, 2026
In Reply: The intersection of CHIP and HIV: Implications for cardiovascular risk stratification.
Journal: Cleveland Clinic journal of medicine
Published: August 03, 2026
Unravelling the mysteries of lipoprotein(a) and coronary disease.
Journal: European journal of preventive cardiology
Published: July 20, 2026
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.
Journal: Journal of the American Heart Association
Published: June 23, 2026
Effect on Lipoprotein(a) Oxidized Phospholipids of Lepodisiran, an Extended-Duration siRNA Targeting Lipoprotein(a).
Journal: Journal of the American College of Cardiology
Published: June 15, 2026
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Journal: Lancet (London, England)
Published: June 13, 2026
Bempedoic Acid and Venous Thromboembolism Risk Among Statin-Intolerant Patients: A Post Hoc Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Journal: JAMA cardiology
Published: May 27, 2026
Factors associated with enhanced LDL cholesterol lowering with bempedoic acid among statin-intolerant patients from CLEAR Outcomes.
Journal: European journal of preventive cardiology
Published: May 19, 2026
Clonal hematopoiesis of indeterminate potential and heart disease: What every internist needs to know.
Journal: Cleveland Clinic journal of medicine
Published: May 01, 2026
Author Correction: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.
Journal: Nature medicine
Published: April 17, 2026
Last Updated: 09/26/2026